Forecasting Hepatitis C liver disease burden on real‐life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?Loreta A. Kondili, Maurizia Rossana Brunetto, Giovanni Raimondo et al.|Liver International|2018Cited by 45
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, S. Fagiuoli, Marco Marzioni et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 19
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosisAntonio Ascione, N. Caporaso, M. De Luca et al.|Infection|2018Cited by 8